Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) rose 6.1% during mid-day trading on Wednesday . The company traded as high as $6.30 and last traded at $6.22. Approximately 283,534 shares traded hands during trading, a decline of 80% from the average daily volume of 1,426,172 shares. The stock had previously closed at $5.86.
Analyst Ratings Changes
TRVI has been the subject of a number of research reports. Wall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. D. Boral Capital reissued a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Trevi Therapeutics in a research note on Tuesday, July 1st. They set an "overweight" rating and a $25.00 target price for the company. HC Wainwright initiated coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They set a "buy" rating and a $21.00 target price for the company. Finally, B. Riley reissued a "buy" rating and set a $20.00 target price (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $20.88.
View Our Latest Analysis on TRVI
Trevi Therapeutics Stock Performance
The company has a market cap of $768.25 million, a price-to-earnings ratio of -14.56 and a beta of 0.46. The firm has a fifty day moving average price of $6.23 and a 200 day moving average price of $5.46.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.04. On average, analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Trevi Therapeutics
Large investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. lifted its holdings in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Trevi Therapeutics during the fourth quarter worth $17,099,000. Vanguard Group Inc. boosted its position in Trevi Therapeutics by 9.4% during the first quarter. Vanguard Group Inc. now owns 3,838,032 shares of the company's stock worth $24,141,000 after purchasing an additional 328,819 shares during the period. Vivo Capital LLC boosted its position in Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after purchasing an additional 1,875,000 shares during the period. Finally, MPM Bioimpact LLC boosted its position in Trevi Therapeutics by 10.8% during the first quarter. MPM Bioimpact LLC now owns 3,428,366 shares of the company's stock worth $21,564,000 after purchasing an additional 333,470 shares during the period. Institutional investors and hedge funds own 95.76% of the company's stock.
Trevi Therapeutics Company Profile
(
Get Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
See Also
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
